Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KAND 567

Drug Profile

KAND 567

Alternative Names: AZD-8797; KAN-0440567; KAND-567

Latest Information Update: 23 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Kancera
  • Class 2 ring heterocyclic compounds; Amines; Analgesics; Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Neuroprotectants; Organic sulfur compounds; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II SARS-CoV-2 acute respiratory disease
  • Phase I Myocardial infarction
  • Preclinical Cardiovascular disorders; Ovarian cancer; Spinal cord injuries
  • No development reported Autoimmune disorders; Breast cancer; Cancer; Cancer pain
  • Discontinued Multiple myeloma

Most Recent Events

  • 21 Apr 2021 Preclinical development is still ongoing in Ovarian cancer in Sweden (PO)
  • 21 Apr 2021 Kancera plans a clinical trial for Ovarian cancer (Second-line therapy or greater) in 2022
  • 28 Mar 2021 No recent reports of development identified for preclinical development in Ovarian-cancer in Sweden (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top